Skip to content
OpenCapital
Get started

OS Therapies OSTX Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

CTO
Citius Oncology, Inc.CTOR
$15.13M+299%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M—
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K—
Free cash flow-$3.7M—

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M—

Returns & leverage

See full
Return on equity470%—
Debt / equity-1.8×—
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's cash provided by (used in) financing activity, including discontinued operation?
OS Therapies (OSTX) reported cash provided by (used in) financing activity, including discontinued operation of $5.21M in Q1 2026.
How has OS Therapies's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
OS Therapies's cash provided by (used in) financing activity, including discontinued operation increased by 394.9% year-over-year, from $1.05M to $5.21M.
What is the long-term trend for OS Therapies's cash provided by (used in) financing activity, including discontinued operation?
Over 2 years (2023 to 2025), OS Therapies's cash provided by (used in) financing activity, including discontinued operation has grown at a 81.3% compound annual growth rate (CAGR), from $2.87M to $9.44M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.